Navigation Links
OXYMATIC® 411A Electronic Oxygen Conserver

ProductsOXYMATIC® 411A Electronic Oxygen Conserver
Company CHAD Therapeutics, Inc.
Item OXYMATIC® 411A Electronic Oxygen Conserver
Features 
  • Every Breath Delivery with Built-in Aluminum Body Regulator with Brass Components (Continuous flow preset at 2 lpm)
  • Weighs approximately 1.2 lbs (544 grams) with the battery
  • Provides every-breath or alternate-breath delivery with a built-in regulator.
  • Offers 1-6 lpm flow equivalency settings to service a broad range of patients.
  • Delivers fixed pulse of oxygen within the first 200 milliseconds of inspiration.
  • Easy access to the battery compartment.
    • Description An All-In-One Conserver.

    Offers an average 5:1 increase in usage time at all settings.

    Allows the use of a standard cannula.

    The combination of the OXYMATIC conserver and lightweight cylinders offers ambulatory oxygen patients a superior alternative to liquid oxygen.

    Reliability backed by a 2-year warranty.

    NOTE: Each model has passed the ASTM PS 127-00 regulator ignition safety test.
    Info CHAD Therapeutics, Inc.
    Customer Service: (800) 423-8870
    Web site: http://www.chadtherapeutics.com

    Related medicine products :

    1. OXYMATIC® 401 Electronic Oxygen Conserver
    2. OXYMATIC® 401A Electronic Oxygen Conserver
    3. OXYMATIC® 411 Electronic Oxygen Conserver
    4. OXYMATIC® 411AF Electronic Oxygen Conserver
    5. SEQUOIA OXYMATIC® 302 Electronic Oxygen Conserver
    6. SEQUOIA OXYMATIC® 312 Electronic Oxygen Conserver
    7. OXYMATIC® 2400 Electronic Oxygen Conserver
    8. SEQUOIA OXYMATIC® 311 Electronic Oxygen Conserver
    9. MaximEyes Practice Management and Electronic Medical Records Software Solutions
    10. PRAXIS® Electronic Medical Records v. 2.19
    11. MaximEyes Optometric & Ophthalmology Software for Practice Management and Electronic Medical Records
    Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Humans damaging the oceans 9411 1Humans damaging the oceans 9411 2Humans damaging the oceans 9411 3Bizarre walking bat has ancient heritage 9408 1Bizarre walking bat has ancient heritage 9408 2Organic food not nutritionally better than conventionally produced food 9405 1Organic food not nutritionally better than conventionally produced food 9405 2